计算溶液所需的质量、体积或浓度。
Enfortumab vedotin-ejfv (anti-Nectin-4) (Ab175528) - ELISA
Immobilized Recombinant Human Nectin-4 protein (rp183631) at 1.0 μg/mL can bind Enfortumab vedotin-ejfv (anti-Nectin-4) (Ab175528) with the EC50 of 17.59 ng/mL.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| Ab175528-100μg |
100μg |
现货 ![]() |
| |
| Ab175528-1mg |
1mg |
现货 ![]() |
| |
| Ab175528-5mg |
5mg |
现货 ![]() |
| |
| Ab175528-10mg |
10mg |
期货 ![]() |
|
| 产品名称 | Enfortumab vedotin-ejfv (anti-Nectin-4), 果胶细胞粘附分子 4 抗体 |
|---|---|
| 别名 | 维恩妥尤单抗 | 恩诺单抗 | 恩福单抗维多汀-ejfv(抗 Nectin-4) |
| 英文别名 | DKFZp686K05193 antibody | EDSS1 antibody | Ig superfamily receptor LNIR antibody | Nectin 4 antibody | Nectin-4 antibody | poliovirus receptor-related 4 antibody | Processed poliovirus receptor-related protein 4 antibody | PRR4 antibody | pvrl4 antibody | |
| 规格或纯度 | 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥90%(SDS-PAGE&SEC-HPLC), 见COA |
| 宿主种属 | 人(Human) |
| 特异性 | NECTIN |
| 种属反应性 | 人(Human),小鼠(Mouse),食蟹猴(Cynomolgus monkey) |
| 偶联 | MC-VC-PAB-MMAE |
| 作用类型 | 抗体 |
| 作用机制 | 果胶细胞粘附分子 4 抗体 |
| 克隆类型 | 重组抗体 |
|---|---|
| Format | Whole IgG |
| 亚型 | Human IgG1 |
| 轻链亚型 | kappa |
| SDS-PAGE | 143.9 kDa |
| 纯化方法 | Protein A purified |
| 纯度 | >90% (SDS-PAGE&SEC) |
| 物理外观 | Liquid |
| 储存缓冲液 | Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
| 浓度 | 见COA |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。 |
| CAS编号和信息 | 1346452-25-2 |
| 分子类型 | 抗体偶联药物 |
Enfortumab vedotin-ejfv (anti-Nectin-4) (Ab175528) - ELISA
Immobilized Recombinant Human Nectin-4 protein (rp183631) at 1.0 μg/mL can bind Enfortumab vedotin-ejfv (anti-Nectin-4) (Ab175528) with the EC50 of 17.59 ng/mL.
Enfortumab vedotin-ejfv (anti-Nectin-4) (Ab175528) - SEC
The purity of Enfortumab vedotin-ejfv (anti-Nectin-4) (Ab175528) is more than 95% verified by HPLC.
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 1. Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, Raitano A, Nadell R, Liu W, Lortie DR et al.. (2016) Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.. Cancer Res, 76 (10): (3003-13). [PMID:27013195] |
| 2. McGregor BA, Sonpavde G. (2019) Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.. Expert Opin Investig Drugs, 28 (10): (821-826). [PMID:31526130] |
| 3. Hanna KS. (2020) Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma.. Drugs, 80 (1): (1-7). [PMID:31823332] |